Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-HNSCC: volrustomig versus observation after definitive concurrent chemoradiotherapy in unresectable locally advanced head and neck squamous cell carcinoma
CTR20244969Phase 3Active
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Volrustomig sequential therapy with Observation (2 arms). Primary endpoint: Progression-free survival. Started May 2025; status: active.
02
Drugs
volrustomig
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20244969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244969.